Dyslipidemia in Patients with Angiographically Confirmed Coronary Artery Disease--an Opportunity for Improvement

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2004 Nov 24

PMID 15553311

Authors

Sanjaya Khanal

Omar Obeidat

Mei Lu

Lori Douthat

Michael P Hudson

Adam B Greenbaum

Aaron Kugelmass

W Douglas Weaver

Affiliations

Soon will be listed here.

Abstract

Background: There are few data about lipid profiles in unselected patients with angiographically confirmed coronary artery disease (CAD).

Hypothesis: The study was undertaken to investigate the demographics, clinical characteristics, angiographic findings, and baseline lipid status of 1,000 consecutive unselected patients with angiographically confirmed CAD.

Methods: Between April 2001 and July 2002, we obtained informed consent and prospectively collected clinical characteristics, fasting lipid profiles, and angiographic results from 1,000 sequential patients with CAD confirmed by angiography.

Results: In these patients with confirmed CAD, 78% had history of hyperlipidemia. Although 62% were receiving lipid-lowering therapy, only 46% had a low-density lipoprotein target of < 100 mg/dl, and only 20% had achieved all four National Cholesterol Education Program-recommended lipid targets.

Conclusions: Better strategies to ensure optimal lipid levels are required. One such method using computerized workflow is being evaluated in this population.

References

CASTELLI W, Anderson K, Wilson P, Levy D . Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992; 2(1-2):23-8. DOI: 10.1016/1047-2797(92)90033-m. View

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

PEARSON T, Laurora I, Chu H, Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4):459-67. DOI: 10.1001/archinte.160.4.459. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Pekkanen J, Linn S, Heiss G, Suchindran C, Leon A, Rifkind B . Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990; 322(24):1700-7. DOI: 10.1056/NEJM199006143222403. View

Marcelino J, Feingold K . Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996; 100(6):605-10. DOI: 10.1016/s0002-9343(96)00011-3. View

Pedersen T, Kjekshus J, Berg K, Olsson A, Wilhelmsen L, Wedel H . Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996; 93(10):1796-802. DOI: 10.1161/01.cir.93.10.1796. View

Shepherd J, Hunninghake D, Barter P, McKenney J, Hutchinson H . Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003; 91(5A):11C-17C; discussion 17C-19C. DOI: 10.1016/s0002-9149(03)00004-3. View

10.

Assmann G, Schulte H, Funke H, von Eckardstein A . The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998; 19 Suppl M:M8-14. View

11.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

12.

Assmann G, Schulte H, von Eckardstein A, Huang Y . High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996; 124 Suppl:S11-20. DOI: 10.1016/0021-9150(96)05852-2. View

13.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

14.

Downs J, Clearfield M, Weis S, Whitney E, Shapiro D, Beere P . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279(20):1615-22. DOI: 10.1001/jama.279.20.1615. View

15.

de Grooth G, Kuivenhoven J, Stalenhoef A, de Graaf J, Zwinderman A, Posma J . Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002; 105(18):2159-65. DOI: 10.1161/01.cir.0000015857.31889.7b. View

16.

Rubins H, Robins S, Collins D, Fye C, Anderson J, Elam M . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341(6):410-8. DOI: 10.1056/NEJM199908053410604. View

17.

FRICK M, ELO O, Haapa K, Heinonen O, Heinsalmi P, Helo P . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20):1237-45. DOI: 10.1056/NEJM198711123172001. View

18.

Yusuf S, Anand S . Cost of prevention. The case of lipid lowering. Circulation. 1996; 93(10):1774-6. DOI: 10.1161/01.cir.93.10.1774. View